News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Breathtec Release: Successful Completion Of Private Placement



11/29/2016 11:17:48 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs

VANCOUVER, BC--(Marketwired - November 28, 2016) -


NOT FOR DISTRIBUTION TO US NEWSWIRE SERVICES NOR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA

Breathtec Biomedical, Inc., (CSE: BTH) ("Breathtec" or the "Company") is pleased to announce that it is has completed a non-brokered private placement financing raising $1,087,400 by the issuance of 14,498,664 units at $0.075 per unit. Each unit consists of one common share ("Share") and one transferable, common share purchase warrant ("Warrant"). Each Warrant will entitle the holder to purchase an additional Share at $0.15 for a period of three years from the date of closing.

The Company did not pay finders' fees in respect of the financing. The Shares, and any Shares issued on the exercise of the Warrants, are subject to a restricted resale period under Canadian securities law and cannot be traded before March 26, 2017.

The proceeds of the offering will be used by Breathtec to support new business efforts and for general corporate purposes.

For more information, please visit: www.breathtecbiomedical.com.

ON BEHALF OF THE BOARD

"Kal Malhi"
President & Director

The CSE has neither approved nor disapproved the information contained herein.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to satisfy the conditions of the Canadian Securities Exchange and other risks detailed from time to time in the filings made by the Company with securities regulations.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.


For further information, please contact:
Investor Relations
Telephone: +1 (352) 327-3152
Email: investors@breathtecbiomedical.com


Read at BioSpace.com


comments powered by Disqus
Breathtec
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES